Summary of clinical studies of ABCG2 expression in human leukemia
| Study | Sample | Results |
|---|---|---|
| AML | ||
| Sargent et al., 2001 | 20 Blast samples | Twenty-seven percent (27%) of samples were ABCG2 positive. |
| van der Kolk et al., 2002 | 20 Paired (pretreatment and refractory/relapse) samples | Low ABCG2 expression, no increase in relapse samples. |
| Abbott et al., 2002 | 40 De novo samples | Seventy-eight percent (78%) of samples had higher ABCG2 expression than normal blood and bone marrow; 7% had levels within the range of drug-resistant cell lines. |
| van Den Huevel-Eibrink et al., 2002 | 20 Paired (de novo and refractory/relapsed) samples | Relapsed samples had higher ABCG2 expression, ABCG2 expression associated with P-gp expression. |
| van der Pol et al., 2003 | 45 Paired samples | No ABCG2 detected. |
| Galimberti et al., 2004 | 51 AML samples | ABCG2 expression detected in 56% of samples, intermediate levels in 48.2%. ABCG2 expression associated with P-gp expression. |
| Suvannasankha et al., 2004 | 31 Pretreatment blast samples | No correlation between function, protein, or gene expression. |
| Steinbach et al., 2002 | 59 Untreated AML, 9 relapse samples | Median ABCG more than 10× higher in patients who did not achieve remission compared with responders. ABCG2 expression higher at relapse than diagnosis. High ABCG2 linked to worse prognosis. |
| Benderra et al., 2005 | 149 De novo samples | ABCG2 expression and ABCG2 expression associated with P-gp function were correlated with poorer treatment outcomes: achievement of complete remission, 4-year disease-free survival and 4-year overall survival. |
| Uggla et al., 2005 | 40 AML samples | Patients with higher ABCG2 expression who respond to therapy had shorter overall survival. No difference in expression between responders and nonresponders. |
| ALL | ||
| Sauerbrey et al., 2002 | 47 De novo, 20 relapsed samples | No correlation between expression and response, ABCG2 expression lower in T-cell lineages. |
| Plasschaert et al., 2003 | 46 De novo samples | BXP-34 positivity in B-cell lineage 2.4-fold higher than T-cell lineage. |
| Stam et al., 2004 | 13 Noninfant and 13 infant samples | ABCG2 expression 2.4-fold less in infant samples. Expression correlated with Ara-C resistance. |
| Suvannasankha et al., 2004 | 30 Pretreatment samples | 43% of cases BXP-21 positive. BXP-21 staining predictive of shorter disease-free survival. |